Premium
RITUXIMAB‐DOSE‐ADJUSTED EPOCH (R‐DA‐EPOCH) IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL): REAL‐LIFE EXPERIENCE ON 190 PATIENTS FROM 3 MEDITERRANEAN COUNTRIES
Author(s) -
Vassilakopoulos T.,
Ferhanoglu B.,
Horowitz N.,
Mellios Z.,
Kaynar L.,
Zektser M.,
Symeonidis A.,
Piperidou A.,
Kalpadakis C.,
Akay O. M.,
Atalar A. C.,
Katodritou E.,
Leonidopoulou T.,
Papageorgiou S.,
Tadmor T.,
Gutwein O.,
Karakatsanis S.,
Ganzel C.,
Karianakis G.,
Isenberg G.,
Gainaru G.,
Vrakidou E.,
Palassopoulou M.,
Ozgur M.,
Siakantaris M.,
Paydas S.,
Tsirigotis P.,
Tsirogianni M.,
Hatzimichael E.,
Tuglular T.,
Chatzidimitriou C.,
Megalakaki E.,
Kanellias N.,
Zikos P.,
Koumarianou A.,
GafterGvili A.,
Angelopoulou M.,
Karmiris T.,
Gurion R.
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.76_2880
Subject(s) - medicine , rituximab , epoch (astronomy) , radiation therapy , lymphoma , gastroenterology , pediatrics , surgery , stars , physics , astronomy